Patents by Inventor Seamus Mulligan

Seamus Mulligan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20240058313
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: October 16, 2023
    Publication date: February 22, 2024
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • Sustained release aminopyridine composition
    Patent number: 11786514
    Abstract: A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: October 17, 2023
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • Sustained Release Aminopyridine Composition
    Publication number: 20230293505
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 21, 2023
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20220401426
    Abstract: A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: June 22, 2022
    Publication date: December 22, 2022
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20220265624
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: May 12, 2022
    Publication date: August 25, 2022
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20220142999
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: January 28, 2022
    Publication date: May 12, 2022
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20220016094
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 20, 2022
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20210308112
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 7, 2021
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20210059996
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 4, 2021
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20200338053
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: July 10, 2020
    Publication date: October 29, 2020
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20200230122
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 23, 2020
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20200093809
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 26, 2020
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20190381020
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: August 29, 2019
    Publication date: December 19, 2019
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20190240206
    Abstract: A pharmaceutical composition which comprises a therapeuticallly effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 8, 2019
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20190231763
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 1, 2019
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20190134015
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: January 4, 2019
    Publication date: May 9, 2019
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20180369216
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for examples, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 27, 2018
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20180256555
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 13, 2018
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • Sustained Release Aminopyridine Composition
    Publication number: 20180125790
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulations, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: January 5, 2018
    Publication date: May 10, 2018
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
    Publication number: 20180055774
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: November 2, 2017
    Publication date: March 1, 2018
    Applicant: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers